

## ASX Announcement

### Investor Webinar – MAST study update

---

**Sydney, Australia, 7 November 2023:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce it will hold an investor webinar on Wednesday 8 November 2023 at 11am AEDT. The session will be hosted by Managing Director and CEO Leslie Chong, alongside the Company's Chief Medical Officer Dr Paul Woodard.

The webinar will discuss today's ASX announcement regarding the clinical trial update of Imugene's Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

Register for the webinar at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_GAxzRb5hS1SRDzbviBQTLQ](https://us02web.zoom.us/webinar/register/WN_GAxzRb5hS1SRDzbviBQTLQ)

After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link shortly after the conclusion of the session.

Investors are encouraged to send questions prior to the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**  
[shareholderenquiries@imugene.com](mailto:shareholderenquiries@imugene.com)

**Media Enquiries**  
Matt Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)



Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

## **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*